13 Jun 2018
The Competition Appeal Tribunal sets aside the UK Competition and Markets Authority’s excessive pricing decision
Following an increase of up to 2,600 per cent in the price of their anti-epilepsy drug, the UK Competition and Markets Authority fined Pfizer and Flynn Pharma nearly £90 million for unfair prices charged to the NHS. In its judgment, the Competition Appeal Tribunal has since set aside the authority’s fine. This briefing considers whether the judgment signals the end of excessive pricing cases.
This material is provided for general information only. It does not constitute legal or other professional advice.
Are you sure want to delete comment ?
Scan this QR Code to share this content
